| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5656362 | HPB | 2017 | 9 Pages |
Abstract
Adjuvant interferon-based chemoradiation for PDAC improves long-term survival compared to standard therapy. However, recurrence rates and long-term complications remain high, thus further studies are indicated to assess patient characteristics that indicate a favorable treatment profile.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Kerri A. Ohman, Jingxia Liu, David C. Linehan, Marcus C. Tan, Benjamin R. Tan, Ryan C. Fields, Steven M. Strasberg, William G. Hawkins,